Description General description A cell-permeable and orally available sulfonanilide that acts as a COX-2-selective non-steroidal anti-inflammatory drug (NSAID). Shown to exhibit 500-fold greater potency in inhibiting the LPS-induced (IC50 = 316 nM in human mononuclear cells) than the non-induced/constitutive (IC50 = 160 µM in human platelets) TxB2 production in vitro and effectively alleviate warm ischemia-reperfusion injury in the canine liver and rat lung in vivo. Packaging 5 mg in Glass bottle Packaged under inert gas Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Otani, Y., et al. 2007. J. Invest. Surg.20, 175. Sunose, Y., et al. 2001. Transplant Proc.33, 862. Grossman, C.J., et al. 1995. Inflamm. Res.44, 253. Nakamura, K., et al. 1993. Chem. Pharm. Bull.41, 2050. Tsuji, K., et al. 1992. Chem. Pharm. Bull.40, 2399.; Description